As anger rose over prescription drug prices, two Washington lawmakers criticized drug makers for taking advantage of Americans, but wanted numbers to back up their claims. Now a new government report, which they requested, provide those numbers — and also potential ammunition in the fight over drug prices.

From 2006 to 2015, global sales for the pharmaceutical industry, including biotech companies, jumped 45 percent to $775 billion. Two-thirds of all drug makers experienced rising profit margins, which averaged 17 percent in 2015. And from 2008 through 2014, worldwide R&D spending — most of which went to drug development, rather than research — increased 8.5 percent, to $89 billion.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy